Aliskiren/hydrochlorothiazide
Combination of | |
---|---|
Aliskiren | Renin inhibitor |
Hydrochlorothiazide | Diuretic |
Clinical data | |
Trade names | Tekturna HCT, Rasilez HCT, others |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Aliskiren/hydrochlorothiazide, sold under the brand name Tekturna HCT among others, is a fixed-dose combination medication for the treatment of hypertension (high blood pressure).[1][2] It contains aliskiren, a renin inhibitor, and hydrochlorothiazide, a diuretic.[1][2] It is taken by mouth.[1]
The most common side effect is diarrhea.[2]
Aliskiren/hydrochlorothiazide was approved for medical use in the United States in January 2008,[3] and for use in the European Union in January 2009.[2]
Medical uses
Aliskiren/hydrochlorothiazide is indicated for the treatment of essential hypertension in adults.[2]
References
- 1 2 3 4 "Tekturna HCT- aliskiren hemifumarate and hydrochlorothiazide tablet, film coated". DailyMed. 7 January 2020. Retrieved 26 August 2020.
- 1 2 3 4 5 6 "Rasilez HCT EPAR". European Medicines Agency. Retrieved 27 August 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Drug Approval Package: Tekturna HCT (aliskiren/hydrochlorothiazide) NDA #022107". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 27 August 2020.
- Lay summary in: "Center for Drug Evaluation and Research: Application Number: 22-107: Summary review" (PDF). U.S. Food and Drug Administration (FDA).
External links
- "Aliskiren hemifumarate mixture with hydrochlorothiazide". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.